Oxford Immunotec (OXFD) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Oxford Immunotec Reports First Quarter 2017 Financial Results
May 2, 2017 7:00 AM EDTFirst quarter revenue of $21.5 million, an increase of 26% compared to prior year periodFirst quarter Tuberculosis revenue of $18.5 million, an increase of 8% compared to prior year periodFirst quarter Tick-borne disease and other revenue of $3.0 million
OXFORD, United Kingdom and MARLBOROUGH, Mass., May 02, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced first quarter 2017 financial results.
We are very pleased with our performance during the... More
